Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Completes Acquisition of BioReliance

NEW YORK (GenomeWeb News) – Sigma-Aldrich said after the close of the market Tuesday that it has completed the acquisition of BioReliance Holdings for $350 million in cash.

It purchased the firm from Avista Capital Partners, which had acquired BioReliance nearly five years ago from Invitrogen, now part of Life Technologies, for $210 million.

Rockville, Md.-based BioReliance provides biologic, specialized toxicology, and animal health testing to pharmaceutical, biopharmaceutical, diagnostics, and other life science customers. The firm had full-year 2010 revenues of around $110 million and is expected to post double-digit growth for 2011.

BioReliance will become part of SAFC, the custom manufacturing and services business unit of Sigma-Aldrich.

"By leveraging SAFC's industrial media presence and BioReliance's biological testing services, we can provide new and better end-to-end product solutions and services to our biopharmaceutical customers," SAFC President Gilles Cottier, said in a statement. "The alliance also provides an opportunity to leverage our CompoZr zinc finger nuclease technology with BioReliance's Toxicology and Animal Health Services operations for the development of new assays, cell lines and animal models for the Research marketplace."

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.